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Abstract: Preventive therapy in primary care is guided by risk thresholds for future cardiovascular events.
We aimed to assess whether the sensitivity of various risk calculators for the detection of subclinical
carotid atherosclerosis (TPA80) could be improved by lowering risk thresholds in younger age groups. We
compared sensitivity, specificity, and discriminatory performance of SCORE, SCORE-HDL, PROCAM,
AGLA, FRAM and PCE coronary risk calculators to detect total plaque area > 80 mm2 (TPA80), a
coronary risk equivalent, in age groups 40-55, 56-65, 66-75 from Germany (DE, N = 2942) and Switzerland
(CH, N = 2202) during the years 2002 to 2016. All calculators showed good to moderate discriminatory
performance to detect TPA80 with AUC ranging from 0.74 (CH-AGLA) to 0.87 (DE- SCORE), but
the sensitivity of high risk risk thresholds varied widely from 39% for DE-FRAM-CVD to 5% for CH-
AGLA. Lowering of the risk threshold increased sensitivity substantially at the expense of minor losses
in specificity, but the sensitivity generally remained < 45% at the 90% specificity threshold. Current risk
thresholds of American and European coronary risk calculators have a low sensitivity to detect TPA80
in younger individuals.
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Preventive therapy in primary care is guided by risk thresholds for future cardiovascular events.We aimed to as-
sess whether the sensitivity of various risk calculators for the detection of subclinical carotid atherosclerosis
(TPA80) could be improved by lowering risk thresholds in younger age groups. We compared sensitivity, speci-
ficity, and discriminatory performance of SCORE, SCORE-HDL, PROCAM, AGLA, FRAM and PCE coronary risk cal-
culators to detect total plaque area N 80 mm2 (TPA80), a coronary risk equivalent, in age groups 40–55, 56–65,
66–75 from Germany (DE, N=2942) and Switzerland (CH, N=2202) during the years 2002 to 2016. All calcu-
lators showed good to moderate discriminatory performance to detect TPA80 with AUC ranging from 0.74 (CH-
AGLA) to 0.87 (DE- SCORE), but the sensitivity of high risk risk thresholds varied widely from 39% for DE-FRAM-
CVD to 5% for CH-AGLA. Lowering of the risk threshold increased sensitivity substantially at the expense ofminor
losses in specificity, but the sensitivity generally remained b45% at the 90% specificity threshold.
Current risk thresholds of American and European coronary risk calculators have a low sensitivity to detect
TPA80 in younger individuals.








Tests used in clinical and preventive medicine have a certain sensi-
tivity (disease detection rate in those with disease) and specificity
(rate of exclusion of a disease in those without the disease). In preven-
tivemedicine, 10-year risk estimates are calculated and in general lower
treatment thresholds are associated with a higher sensitivity and a
lower specificity. In the Framingham Offspring Study coronary risk pre-
diction was improved by reducing risk thresholds in younger subjects
(Navar-Boggan et al., 2015a).
While a clinician's preventive efficacy is dependent on meaningful
sensitivity thresholds, tests need proof with regards to their discrimina-
tory value. By taking the whole range of test results, a plot of sensitivity
and specificity is created by receiver operating curves (ROC) to detect
thosewith a future event. Acceptable area under the curve (AUC) is usu-
ally larger than 0.80.
Such calculations are based on cardiovascular events occurring over
time. By definition, such an approach translates observations from the
past into the present. A “present time” validation to assesses the accura-
cy of coronary risk calculators can be derived frompatients admitted for
a first myocardial infarction, where a very low sensitivity was revealed
for the European calculator (SCORE-CVD (Conroy et al., 2003)) risk
threshold of 5% (Mortensen et al., 2015; Mortensen & Falk, 2014). In-
stead ofwaiting until amyocardial infarction occurs, atherosclerosis im-
aging also offers a “present time” validation for coronary risk calculators
by measuring the total carotid plaque burden. Such information can
therefore be used to test risk calculators for their performance before
the occurrence of an acute coronary event and may help to define sen-
sitivity cutoffs in those populations, where atherosclerosis burden infor-
mation is available (Arbab-Zadeh & Fuster, 2015).
For the purpose of this study, we used a total plaque area of greater
than or equal to 80mm2 (TPA80), forwhich a coronary risk of N20%was
Preventive Medicine Reports 6 (2017) 182–186
⁎ Corresponding author.
E-mail address: michel.romanens@gmail.com (M. Romanens).
http://dx.doi.org/10.1016/j.pmedr.2017.03.006
2211-3355/© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Contents lists available at ScienceDirect
Preventive Medicine Reports
j ourna l homepage: ht tp : / /ees.e lsev ie r .com/pmedr
found in a long-term observational study (median observation time
15.4 years) in 6257 subjects from the Norwegian Tromsø area (Hald et
al., 2013) in order to test the performance of various risk calculators
for their sensitivity and specificity in three different age.
2. Materials and methods
2.1. Subject selection
Subjects were assessed at the practice based level as described else-
where (Romanens et al., 2014; Romanens et al., 2011). In the Swiss (CH)
Imaging Center in Olten, subjects were referred by their primary care
physician (57%) or self-referred to the vascular risk foundation (43%;
www.varifo.ch). In the German (DE) Center in Koblenz, all subjects
were referred within a workplace medicine setting (Adams & Bojara,
2015). Subjects had to be free of cardiovascular symptoms or diseases.
Themedical history was assessed, laboratory values, blood pressure de-
termined locally and entered into a data spread-sheet (Excel, Microsoft,
Richmond, USA).
2.2. Ethical aspects
Subjectswith self-referral to theVascular Risk Foundation gavewrit-
ten consent. The study protocol was approved by the local ethical com-
mittee of Solothurn, Switzerland. Practice based subjects were entered
into an anonymized study registry, forwhich current legislation in Swit-
zerland and Germany does not require formal ethical committee
consent.
2.3. Carotid imaging
Burden of longitudinal carotid plaque surface was imaged with a
high resolution ultrasound linear transducer probe (7.5–12.0 MHz),
which identified plaqueswith intimal thickening ≥1.0mm. The longitu-
dinal area of all plaques was summed up to the total plaque area (TPA)
in mm2. All TPA measurements were made by A.A. in Koblenz and by
M.R. in Olten. A TPA ≥ 80 mm2 (TPA80) defined a coronary risk equiva-
lent (risk N20% for fatal and non-fatal myocardial infarction in 10 years)
(Hald et al., 2013). Intraobserver reproducibility (MR)was tested for the
right carotid artery in 57 patients with a correlation coefficient of r2
0.964 (left carotid artery: r2 0.944, both arteries r2 0.986). For the cutoffs
of TPA 0–9 mm2, 10–49 mm2, 50–99 mm2 and N100 mm2 Kappa value
was 0.69 (0.54–0.84 95% CI).
2.4. Computation of risk
Cardiovascular riskwas computed using the published risk formulae
in an Excel spread sheet. We used the European Society of Cardiology
risk calculators for low risk populations (SCORE and SCORE-HDL
(Descamps et al., 2012)), the pooled cohort equation (PCE (Robinson
& Stone, 2015)) and the Framingham risk calculator for major cardiac
(FRAM-CHD (D'Agostino et al., 2008)) and major cardiovascular events
(FRAM-CVD (D'Agostino et al., 2008)). The German PROCAM risk
(Assmann et al., 2007) was calculated manually online, since the algo-
rithm is not published. For Switzerland, PROCAM risk was multiplied
by the factor 0.7 (CH-AGLA, according to the Swiss AGLA guidelines
2014 (Eckardstein, 2014)). SCORE risk was calculated using the algo-
rithm published by Conroy (Conroy et al., 2003) and the SCORE-HDL
(Cooney et al., 2009) risks were calculated as previously described by
Descamps (Descamps et al., 2012).
2.5. Statistics
We used MedCalc software (Version 13.3.3.0) to calculate ROC
curves and their comparisons (MedCalc Software bvba, 2013). For com-
parison of risk calculators, equivalent SCORE risk was set to be four
times lower than in the remainder, therefore, a PROCAM or FRAM risk
of 20% would correspond to an SCORE risk of 5%. Level of statistical sig-
nificance was set at p b 0.05.
3. Results
3.1. Patient characteristics
We assessed 2202 healthy Swiss and 2942 healthy German subjects.
The characteristics of the study subjects are shown in Table 1. The Swiss
group was older than the German group (57 ± 9 versus 46± 10 years)
with more women (49% versus 34%). Average 10-year risk among
groups was low. Prevalence of TPA80 was 22% in Switzerland and 15%
in Germany. Lipid profiles were comparable.
3.2. Prevalence of TPA80
The prevalence of TPA80was low in Swiss women aged 40–55 years
(4%), but increased to 14% and 36% in the two remaining age groups. For
men, TPA80 was prevalent in all age groups above the 15% level, and
was present in 57% in Swiss men aged 66 to 75 years (Table 2).
3.3. Sensitivity and Specificity of high risk coronary risk thresholds for the
detection of TPA80
Using high risk thresholds for high coronary risk (5% for the SCORE
and SCORE-HDL risk calculators, 20% for the remaining cardiovascular
risk calculators), global sensitivity to detect TPA80 showed some vari-
ability, but was generally below 20% in Switzerland and Germany. Of
note, CH-AGLA had a sensitivity of only 5% (Table 3).
3.4. C-Statistics of coronary risk calculators (Fig. 1)
We found that the performance of all cardiovascular risk calculators
was similar in Switzerland andGermany, butwith slightly higher values
for Germany and with significant differences among calculators (Sup-
plemental Table I): especially CH-AGLA showed a significantly lower
area under the curve (AUC 0.743), while the same was true for the
Table 1
Baseline Characteristics, average and prevalence of cardiovascular risk and average TPA for
Switzerland (CH) and Germany (DE).
Country CH DE
Number of subjects (N) 2202 2942
Female, N, % 1082 49% 989 34%
Mean age (N ± SD) 57 ± 9 46 ± 10
Family history for CAD (N, %) 386 18% 660 22%
Current smoker (N, %) 458 21% 770 26%
Blood pressure systolic, mm Hg mean ± SD 129 ± 16 123 ± 16
TPA mm2 mean ± SD 52 ± 50 36 ± 50
Individuals with TPA ≥ 80 mm2 (N, %) 484 22% 452 15%
Total cholesterol, mmol/l, mean ± SD 5.9 ± 1.2 5.9 ± 1.2
HDL cholesterol, mmol/l, mean ± SD 1.5 ± 0.5 1.4 ± 0.4
LDL cholesterol, mmol/l, mean ± SD 3.7 ± 1.0 3.8 ± 0.9
Triglycerides, mmol/l, mean ± SD 1.5 ± 0.9 1.7 ± 1.2
FRAM-CHD 9.0 ± 7.1 6.5 ± 6.0
% individuals with risk b10% 67% 79%
FRAM-CVD 13.2 ± 9.8 9.3 ± 8.4
% individuals with risk b10% 47% 66%
SCORE 2.4 ± 2.6 1.1 ± 1.4
% individuals with risk b5% 87% 99%
SCORE-HDL 1.8 ± 2.0 0.8 ± 1.2
% individuals with risk b5% 93% 99%
PCE 8.0 ± 7.4 7.8 ± 13.8
% individuals with risk b10% 70% 80%
PROCAM 6.2 ± 7.3 4.3 ± 6.2
% individuals with risk b10% 81% 87%
AGLA 4.3 ± 5.1
% individuals with risk b10% 89%
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DE-PCE risk calculator (AUC 0.769). Good performance was found both
for the FRAM-CVD, SCORE and SCORE-HDL risk calculators.
3.5. Effect of different risk thresholds on sensitivity and specificity to detect
TPA80 by sex and age groups for SCORE, PROCAM and CH-AGLA
Supplemental Tables II to IV show the sensitivity and specificity by
age groups and various risk thresholds for PROCAM and SCORE for
women and men respectively to detect TPA80. Supplemental Tables V
and VI sensitivity of various risk thresholds among different risk algo-
rithms. By increasing risk thresholds sensitivity is reduced to zero or
near zero, with specificities at near 100% or 100%.
4. Discussion
We assessed sensitivity, specificity and discriminatory performance
(area under curve, AUC) aswell as predictive values of several American
and European risk calculators to detect a coronary risk equivalent de-
fined by the total carotid plaque burden (TPA80) in a practice based set-
ting of 5144 subjects from Koblenz (N = 2942) and Olten region (N =
2202). The prevalence range of TPA80 was between 4% in younger
women and 57% in elderly men (Table 2).
Results from ROC curves (Fig. 1) showed acceptable discriminatory
performance to detect TPA80 with (0.74 for CH-AGLA to 0.87 for DE-
SCORE-HDL, Supplemental Table I). Although ROC analysis show gener-
ally good discriminatory performance of coronary risk calculators exter-
nally (DeFilippis et al., 2015), reliance on recalibration based on
predicted-to-observed (P/O) event ratio in cohorts where true nega-
tives by far outweigh numerically true positives usually creates a cali-
bration in favor of true negatives (Navar-Boggan et al., 2015a;
Mortensen et al., 2015; DeFilippis et al., 2015). Such a down-calibration
was performed with the Swiss AGLA coronary risk calculator, thus re-
ducing coronary risk as compared to Germany by 30%.
The high-risk threshold for SCORE (5%) and for the remainder of the
calculators (20%) had sensitivities below 30% except for CH-FRAM-CVD
(39%) and DE-FRAM-CVD (39%). Our results indicate that subjects with
a coronary risk equivalent in mid-life remain frequently undetected
(sensitivity between 5% and 39%, Table 3). Therefore, the conundrum
of risk prediction is not resolved (McEvoy et al., 2014). Risk thresholds
should maintain a specificity of at least 90% and Supplemental Tables
II - IV show that sensitivities usually remain below 25% (especially in
younger women). Our data could help future guideline committees to
use lower decision thresholds in order to detect higher risk individuals
with an increased sensitivity.
Use of total plaque burden is accurate to predict cardiovascular risk
(Baber et al., 2014; Spence & Hackam, 2010; Gottesman et al., 2014).
As confirmed by in the long-term Tromsø study, TPA80 – a rapid and
cheap test that does not require expensive radiology, radiation exposure
or software – is a high risk finding for incident myocardial infarction
(Hald et al., 2013). TPA of 40 ± 22 mm2 derived from the right carotid
artery was associated with an unadjusted coronary risk of 23.9%
(95%CI: 21.2–27.1) in 10 years. The Hazard Ratio per 1-SD increase in
TPA (2.43 mm2) was 1.23 (95%CI: 1.15–1.32) using age as time scale
and adjustments for sex, body mass index, smoking, total cholesterol,
high-density lipoprotein cholesterol, diabetes mellitus, and
hypertension.
Earlier preventive therapy may better protect against harm due to
atherosclerosis later in life, which has been shown for both arterial hy-
pertension (Gottesman et al., 2014) and hypercholesterolemia (Navar-
Boggan et al., 2015b). Statin treatment is still highly effective even in
the fittest (Kokkinos et al., 2012). A five year treatment of 1000 healthy
men aged between 45 and 54 years with pravastatin (40mg/day) saved
the British Health Care System £710,000 over a 15-year period and sav-
ings were even higher (£840′000) in those at low risk (7.5% in 10 years
risk) (Mc Connachie et al., 2014). A 50-year old woman with a CH-
FRAM-CVD risk of 7% and TPA80 has an arterial age of 75 years 7 and a
posttest risk of 35% (Romanens M. VARIFO Cardiovascular Risk
Calculator. 2016. Available from: www.docfind.ch/GPRisk.xlsx).
A low sensitivity for clinical events were confirmed by the Copenha-
gen General Population Study, where 68 fatal and 767 fatal and non-
Table 2
Prevalence (N, %) of TPA80by age groups and sex for Switzerland (CH) andGermany (DE).
CH DE
TPA80 Age group N % N %
Women 40–55 18 4.5 27 4.4
56–65 60 14.0 45 25.7
66–75 78 36.3
Men 40–55 79 15.7 195 17.5
56–65 150 37.2 179 48.2
66–75 97 56.7
All 40–55 97 10.7 222 12.8
56–65 210 25.2 224 41.0
66–75 175 45.3
Table 3
Sensitivity (SENS) and specificity (SPEC) of coronary risk calculators at the high risk
threshold (SCORE 5%, 20% remainders) to detect TPA80.
Switzerland (N = 2202) SENS 95%CI SPEC 95%CI
SCORE 32.64 28.5–37.0 92.08 90.7–93.3
SCORE-HDL 19.21 15.8–23.0 96.33 95.3–97.2
PCE 17.36 14.1–21.0 96.39 95.4–97.2
FRAM-CHD 21.07 17.5–25.0 95.81 94.8–96.7
FRAM-CVD 39.05 34.7–43.6 87.14 85.5–88.7
PROCAM 12.81 10.0–16.1 97.09 96.2–97.8
AGLA 5.17 3.4–7.5 98.95 98.3–99.4
Germany (N = 2942) SENS 95%CI SPEC 95%CI
SCORE 11.73 8.9–15.1 99.4 99.0–99.7
SCORE-HDL 7.3 5.1–10.1 99.64 99.3–99.8
PCE 6.42 4.3–9.1 93.29 92.2–94.2
FRAM-CHD 18.14 14.7–22.0 98.71 98.2–99.1
FRAM-CVD 39.38 34.8–44.1 94.9 94.0–95.7
PROCAM 15.27 12.1–18.9 98.8 98.3–99.2
Fig. 1. Summarized discriminatory performance of FRAM-CVD, SCORE-CVD, PCE and
PROCAM coronary risk calculators to detect total plaque area N 80 mm2 (TPA80) in 5′
144 primary prevention subjects.
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fatal cardiovascular events occurred over an observation time of 7 years.
Sensitivity at the 5% SCORE level was 42% and 26% respectively
(Mortensen et al., 2015).
We were able to replicate the results of the Framingham Offspring
Study for the coronary risk calculators PROCAM/AGLA and SCORE
(Navar-Boggan et al., 2015a). Only at a risk threshold of 0.75% did the
SCORE calculator have acceptable sensitivities and specificities in men
and women aged 40–55. We confirm the study results by Mortensen
et al., who found similar results: of 162 men and 85 women with a
first myocardial infarction, only 8% and 1% respectively would have
qualified for a statin treatment before the event when using a cutoff of
SCORE ≥ 5% (Mortensen & Falk, 2014).
For SCORE and SCORE-HDL, we were able to replicate the results
from the Copenhagen General Population Study, where lower risk
thresholds of 1% rather than of 5% 10 year risk increased the sensitivity
for fatal and non-fatal cardiovascular events from SCORE 26% (SCORE-
HDL 17%) to 79% (SCORE-HDL 71%) in men and women aged 40–
65 years (Mortensen et al., 2015). Counter-intuitively we also con-
firmed the finding that the addition of HDL in the SCOREmodel reduced
the sensitivity of SCORE-HDL when compared to SCORE (Supplemental
Tables V and VI). In a recent survey involving 44,889 subjects aged 40–
75 years a SCORE sensitivity threshold of 2.4% was best suited for
assigning a preventive therapy with statins (Mortensen et al., 2017).
4.1. Study limitations
Our study examines practice based groups of subjects, which cannot
be extrapolated to the entire population. This may also be viewed as a
potential strength of the study, since practice based subjects may
serve as an external validation for coronary risk calculators.
The images were obtained within a clinical setting as part of routine
measurements by two different observers. However, the congruence as
outlined in Table 2 of the findings from Koblenz and Olten may be
viewed as a mutual validation. The total plaque area, a measure of the
total carotid plaque burden anticipated the results of the IMPROVE-IT
study, thus confirming the high prognostic validity of such measure-
ments (Cannon et al., 2015; Spence, 2008; Spence, 2012; Bogiatzi &
Spence, 2012).
We do not present hard coronary outcome data in this study, how-
ever, there is high confidence for TPA80 being a true coronary risk find-
ing and we were able to confirm the poor sensitivity performance of
SCORE-HDL versus SCORE, originally described in the Copenhagen Gen-
eral Population Study (Mortensen et al., 2015). Our approach is in line
with the recommendations of American and European guidelines, to
treat atherosclerosis reported by medical imaging (Mansia et al., 2007;
De Backer et al., 2003; Stone et al., 2014). Validation by plaque imaging
as a tool to test the 2013 ACC/AHA guideline on the treatment of blood
cholesterol to reduce atherosclerotic cardiovascular disease risk guide-
lines is widely accepted for the PCE calculator (Robinson & Stone,
2015; Johnson & Dowe, 2014). Empirical evidence has shown that the
regression of total plaque area over time due to medical intervention
is associated with a statistically significant reduction of cardiovascular
events (Spence et al., 2002).
5. Conclusions
In our practice based group of 5144 subjects without cardiovascular
disease, we find an acceptable discriminatory performance (ROC analy-
sis) of all coronary risk calculators to detect TPA80. In coronary risk
prevention at the individual level, where high sensitivity should exist
to detect subjects with a coronary risk equivalent derived from the
total carotid plaque burden, we observed a poor sensitivity of risk fac-
tor-based assessments when using recommended risk thresholds espe-
cially in subject aged 40–65. We find that improvement in sensitivity
can be achieved by lowering risk thresholds without notable losses in
specificity.
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